Shalby Ltd

Shalby Medtech Limited announced that Deepak Anand has resigned as Chief Executive Officer, effective close of business hours on September 4, 2026, to move abroad for personal reasons, according to a regulatory filing by Shalby Limited on August 18, 2026.

Shalby Limited announced that its Nomination and Remuneration Committee approved the grant of 15,000 Employee Stock Options (ESOPs) convertible into an equal number of Equity Shares of face value Rs 10 each, under the Shalby Limited Employees Stock Options Scheme – 2021, to eligible employees, with an exercise price of Rs 100 per Option. The company noted that the grant utilizes lapsed options and will not increase the company's share capital as the shares are channelized from the secondary market.

Shalby Limited announced the appointment of Mr. Shanay Vikram Shah (DIN: 02726541) as an Additional Director designated as Whole-Time Director for a term of five consecutive years, effective August 12, 2026, following a recommendation from the Nomination and Remuneration Committee and approval from the Audit Committee. Mr. Shah, who is a relative of Dr. Vikram I. Shah, Chairman and Managing Director of Shalby Limited, was previously appointed as President of the company on October 5, 2024, and his appointment as Whole-Time Director is subject to shareholder approval at the 22nd Annual General Meeting scheduled for September 10, 2026.

Shalby Limited announced that 3,000 stock options were exercised on August 10, 2026, under the Shalby Limited Employees Stock Options Scheme – 2021, resulting in the transfer of an equivalent number of equity shares with a face value of Rs 10 each to the option grantees by the Shalby Limited Employee Welfare Trust; the company noted that the exercise did not change the paid-up equity share capital as the shares were sourced from the secondary market, and realized Rs 3,00,000 from the exercise.

Shalby has revised the meeting of the Board of Directors which was scheduled to be held on 5 August 2026. The meeting will now be held on 12 August 2026.

Shalby will hold a meeting of the Board of Directors of the Company on 5 August 2026.

Shalby announced that the 22th Annual General Meeting(AGM) of the company will be held on 10 September 2026.

Net profit of Shalby reported to Rs 18.32 crore in the quarter ended March 2026 as against net loss of Rs 11.02 crore during the previous quarter ended March 2025. Sales rose 8.52% to Rs 287.45 crore in the quarter ended March 2026 as against Rs 264.89 crore during the previous quarter ended March 2025. For the full year,net profit rose 501.13% to Rs 37.39 crore in the year ended March 2026 as against Rs 6.22 crore during the previous year ended March 2025. Sales rose 5.01% to Rs 1141.43 crore in the year ended March 2026 as against Rs 1086.96 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales287.45264.89 9 1141.431086.96 5 OPM %10.217.87 -12.5112.20 - PBDT28.0915.49 81 130.55121.49 7 PBT9.61-0.74 LP 60.5655.73 9 NP18.32-11.02 LP 37.396.22 501 Powered by Capital Market - Live

Shalby announced that the Company'fs step']down subsidiary namely Ningen Lifecare (subsidiary of PK Healthcare) has been struck']off from the Register of Companies by Ministry of Corporate Affairs w.e.f. 12 May 2026 as notified today on MCA website. Accordingly, Ningen Lifecare is now ceased to be subsidiary of PK Healthcare and consequently step']down subsidiary of the Company.

Shalby will hold a meeting of the Board of Directors of the Company on 27 May 2026.